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Introduction Objectives 
Alzheimer disease (AD) is considered the most common cause of dementia, with a 
prevalence of 80% in elderly.  
It is an aged-related disorder characterized by a progressive neurodegeneration 
(especially in the hippocampus and neocortex) that correlates with memory and 
learning impairment. 
These typical features of the disease have been related with deposition of senile 
plaques (accumulation of Aβ peptide) and intracellular neurofibrillary tangles 
(hyperphosphorylated tau protein). 
Moreover, glutamate homeostasis is also altered in AD brains , leading to increased 
levels of extracellular glutamate. This seems to be gaining relevance in the disease 
development and progression.  
Glutamate levels are mainly regulated by astrocytes, which actively participate in 
the synapse events. Thus, astrocytes role is of great importance when targeting AD 
pathogenesis. 
• Describing the physiological cycle of glutamate. 
• Reviewing the current knowledge of dysregulations on glutamate clearance and 
release related to Alzheimer disease progression. 
• Explaining possible causes of such alterations and their consequences. 
Methodology 
Scientific literature search on Pubmed database: paper and reviews were selected by 
relevance on journal and publication date, as well as relevant articles cited in other 
publications. 
Official websites of Alzheimer’s disease organizations and books related to neuroglia 
and glutamate were also consulted. 
Glutamatergic system in Alzheimer disease  
Glutamate cycle under physiological 
Under physiological conditions, glutamate concentration within the synaptic cleft 
remains low. Therefore, the interplay between glutamate release and clearance is 
essential to tightly regulate the extracellular levels of the neurotransmitter and 
thereby preserve synapsis transmission (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Astrocytes are essential to ensure that glutamate concentration is kept low and they 
actively participate in the synapse. In fact, astrocytes have glutamate receptors, so 
when the neurotransmitter is released to the synaptic cleft they can sense it and 
rapidly activate glutamate transporters (EAATs). These transporters are primarily 
responsible for glutamate uptake and are mainly present on astrocytes plasmatic 
membrane.  
Glutamate cycle under pathological conditions 
Glutamatergic system has proven to be profoundly dysregulated in AD. This results in 
elevated glutamate concentrations within the extracellular space, leading to a variety 
of consequences characteristic of the pathogenesis: 
 
 
Several studies support that such alterations may be due to the observed decrease in 
EAATs function and protein levels. Among glutamate transporters, EAAT2/GLT-1 has 
been described to be the most affected in AD brains, since it is the main transporter 
expressed in the hippocampal region. 
Moreover, under pathological conditions astrocytes can further contribute to elevate 
glutamate levels by releasing the neurotransmitter by themselves. This has been 
demonstrated to be in response of pro-inflammatory factors, oxidative stress… 
Consequences of increased glutamate levels 
Elevated concentration of glutamate results in the overstimulation of its receptors, 
especially NMDARs. Consequently, synaptic loss and excitotoxicity are enhanced. It 
has been proposed that depending on NMDAR subunit, different pathways can be 
triggered. Indeed, high glutamate consequences seem to be regulated by different 
subunits [3]: 
 
 
Possible causes of glutamate homeostasis disruption 
The underlying causes of glutamate dysregulation are still not fully  understood. 
However, several studies have related it with Aβ [4,5]: 
Conclusions Selected references 
• Glutamate homeostasis is profoundly impaired in AD and this has been related 
with neurodegeneration, cognitive decline, and neuroinflammation.  
• It is not clear if such alterations are consequence of the disease or could be a 
cause.  
• However, what seems to be more evident is that increasing glutamate levels 
contribute to AD progression. 
• Moreover, focusing on glutamate transporters could be promising as a therapy. 
• Therefore, it would be interesting to conduct further studies in order to better 
understand the mechanisms and consequences involved in their dysregulation. 
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Figure 1. Glutamate physiological cycle: glutamate (Glu) is synthesized from glutamine (Gln) and then stored into 
synaptic vesicles. After neuronal excitation, glutamate is released into the synaptic cleft and binds to glutamate 
receptors (NMDAR, AMPAR, mGluR1-5). The neurotransmitter is rapidly cleared by glutamate transporters (EAAT) 
mainly present in glial cells. Once inside glial cells, glutamate is converted to glutamine, which is recycled back to 
the presynaptic neuron. [From: Nat. Rev. Neurosci. 13, 22-37 (2012)] 
• Glu2B  Excitotoxicity (tau-dependent pathway) 
• Glu2A  Synaptic loss (caspase signaling tau-independent pathway) 
